Header Logo

Connection

Resham Bhattacharya to Humans

Back to Details
This is a "connection" page, showing publications Resham Bhattacharya has written about Humans.
Resham Bhattacharya
Connection Strength
1.005
Humans
  1. A role for the cystathionine-?-synthase /H2S axis in astrocyte dysfunction in the aging brain. Redox Biol. 2023 Dec; 68:102958.
    View in: PubMed
    Score: 0.051
  2. When the chains do not break: the role of USP10 in physiology and pathology. Cell Death Dis. 2020 12 04; 11(12):1033.
    View in: PubMed
    Score: 0.042
  3. Reality CHEK: Understanding the biology and clinical potential of CHK1. Cancer Lett. 2021 01 28; 497:202-211.
    View in: PubMed
    Score: 0.041
  4. KRCC1: A potential therapeutic target in ovarian cancer. FASEB J. 2020 02; 34(2):2287-2300.
    View in: PubMed
    Score: 0.039
  5. Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer. Mol Cancer Ther. 2018 10; 17(10):2136-2143.
    View in: PubMed
    Score: 0.035
  6. Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer. Mol Cancer Ther. 2018 01; 17(1):39-49.
    View in: PubMed
    Score: 0.034
  7. BMI1, a new target of CK2a. Mol Cancer. 2017 03 07; 16(1):56.
    View in: PubMed
    Score: 0.032
  8. Mitochondrial BMI1 maintains bioenergetic homeostasis in cells. FASEB J. 2016 12; 30(12):4042-4055.
    View in: PubMed
    Score: 0.031
  9. MDR1 mediated chemoresistance: BMI1 and TIP60 in action. Biochim Biophys Acta. 2016 08; 1859(8):983-93.
    View in: PubMed
    Score: 0.031
  10. Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget. 2016 Mar 22; 7(12):15093-104.
    View in: PubMed
    Score: 0.030
  11. Inhibition of BMI1 induces autophagy-mediated necroptosis. Autophagy. 2016; 12(4):659-70.
    View in: PubMed
    Score: 0.030
  12. Cystathionine ß-synthase regulates endothelial function via protein S-sulfhydration. FASEB J. 2016 Jan; 30(1):441-56.
    View in: PubMed
    Score: 0.029
  13. Role of TGF-ß signaling in uterine carcinosarcoma. Oncotarget. 2015 Jun 10; 6(16):14646-55.
    View in: PubMed
    Score: 0.028
  14. NHERF-2 maintains endothelial homeostasis. Blood. 2012 May 17; 119(20):4798-806.
    View in: PubMed
    Score: 0.023
  15. Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer. PLoS One. 2011 Mar 21; 6(3):e17918.
    View in: PubMed
    Score: 0.021
  16. MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res. 2009 Dec 01; 69(23):9090-5.
    View in: PubMed
    Score: 0.019
  17. Distinct role of PLCbeta3 in VEGF-mediated directional migration and vascular sprouting. J Cell Sci. 2009 Apr 01; 122(Pt 7):1025-34.
    View in: PubMed
    Score: 0.019
  18. Role of hedgehog signaling in ovarian cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7659-66.
    View in: PubMed
    Score: 0.018
  19. Biological properties of "naked" metal nanoparticles. Adv Drug Deliv Rev. 2008 Aug 17; 60(11):1289-1306.
    View in: PubMed
    Score: 0.017
  20. Regulatory role of dynamin-2 in VEGFR-2/KDR-mediated endothelial signaling. FASEB J. 2005 Oct; 19(12):1692-4.
    View in: PubMed
    Score: 0.014
  21. Inhibition of vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis by the Kruppel-like factor KLF2. J Biol Chem. 2005 Aug 12; 280(32):28848-51.
    View in: PubMed
    Score: 0.014
  22. Uterine carcinosarcoma: Unraveling the role of epithelial-to-mesenchymal transition in progression and therapeutic potential. FASEB J. 2024 Nov 15; 38(21):e70132.
    View in: PubMed
    Score: 0.014
  23. Complexity in the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF)-receptors signaling. Mol Cell Biochem. 2004 Sep; 264(1-2):51-61.
    View in: PubMed
    Score: 0.013
  24. Primary Human Breast Cancer-Associated Endothelial Cells Favor Interactions with Nanomedicines. Adv Mater. 2024 Jul; 36(28):e2403986.
    View in: PubMed
    Score: 0.013
  25. Deciphering a GPCR-lncrna-miRNA nexus: Identification of an aberrant therapeutic target in ovarian cancer. Cancer Lett. 2024 Jun 01; 591:216891.
    View in: PubMed
    Score: 0.013
  26. Induction of apoptosis in human cancer cell lines by diospyrin, a plant-derived bisnaphthoquinonoid, and its synthetic derivatives. Cancer Lett. 2002 Dec 15; 188(1-2):85-93.
    View in: PubMed
    Score: 0.012
  27. Gold Nanoparticles Disrupt the IGFBP2/mTOR/PTEN Axis to Inhibit Ovarian Cancer Growth. Adv Sci (Weinh). 2022 11; 9(31):e2200491.
    View in: PubMed
    Score: 0.012
  28. Revealing macropinocytosis using nanoparticles. Mol Aspects Med. 2022 02; 83:100993.
    View in: PubMed
    Score: 0.011
  29. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1. Autophagy. 2021 Jan; 17(1):1-382.
    View in: PubMed
    Score: 0.011
  30. MicroRNA-195 controls MICU1 expression and tumor growth in ovarian cancer. EMBO Rep. 2020 10 05; 21(10):e48483.
    View in: PubMed
    Score: 0.010
  31. Switching the intracellular pathway and enhancing the therapeutic efficacy of small interfering RNA by auroliposome. Sci Adv. 2020 07; 6(30):eaba5379.
    View in: PubMed
    Score: 0.010
  32. Ubiquitin-binding associated protein 2 regulates KRAS activation and macropinocytosis in pancreatic cancer. FASEB J. 2020 09; 34(9):12024-12039.
    View in: PubMed
    Score: 0.010
  33. Cystathionine beta synthase regulates mitochondrial dynamics and function in endothelial cells. FASEB J. 2020 07; 34(7):9372-9392.
    View in: PubMed
    Score: 0.010
  34. Analysing the nanoparticle-protein corona for potential molecular target identification. J Control Release. 2020 06 10; 322:122-136.
    View in: PubMed
    Score: 0.010
  35. Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro. Int J Nanomedicine. 2020; 15:991-1003.
    View in: PubMed
    Score: 0.010
  36. Hydrogen sulfide signaling in mitochondria and disease. FASEB J. 2019 12; 33(12):13098-13125.
    View in: PubMed
    Score: 0.010
  37. Protein kinase D up-regulates transcription of VEGF receptor-2 in endothelial cells by suppressing nuclear localization of the transcription factor AP2ß. J Biol Chem. 2019 10 25; 294(43):15759-15767.
    View in: PubMed
    Score: 0.010
  38. Nanoparticle Interactions with the Tumor Microenvironment. Bioconjug Chem. 2019 09 18; 30(9):2247-2263.
    View in: PubMed
    Score: 0.010
  39. Gold Nanoparticle Transforms Activated Cancer-Associated Fibroblasts to Quiescence. ACS Appl Mater Interfaces. 2019 Jul 24; 11(29):26060-26068.
    View in: PubMed
    Score: 0.009
  40. Gold Nanoparticles Disrupt Tumor Microenvironment - Endothelial Cell Cross Talk To Inhibit Angiogenic Phenotypes in Vitro. Bioconjug Chem. 2019 06 19; 30(6):1724-1733.
    View in: PubMed
    Score: 0.009
  41. Multifunctional APJ Pathway Promotes Ovarian Cancer Progression and Metastasis. Mol Cancer Res. 2019 06; 17(6):1378-1390.
    View in: PubMed
    Score: 0.009
  42. Probing Cellular Processes Using Engineered Nanoparticles. Bioconjug Chem. 2018 06 20; 29(6):1793-1808.
    View in: PubMed
    Score: 0.009
  43. Cystathionine ß-synthase regulates mitochondrial morphogenesis in ovarian cancer. FASEB J. 2018 08; 32(8):4145-4157.
    View in: PubMed
    Score: 0.009
  44. MICU1 drives glycolysis and chemoresistance in ovarian cancer. Nat Commun. 2017 05 22; 8:14634.
    View in: PubMed
    Score: 0.008
  45. Gold Nanoparticle Reprograms Pancreatic Tumor Microenvironment and Inhibits Tumor Growth. ACS Nano. 2016 12 27; 10(12):10636-10651.
    View in: PubMed
    Score: 0.008
  46. Role of cystathionine beta synthase in lipid metabolism in ovarian cancer. Oncotarget. 2015 Nov 10; 6(35):37367-84.
    View in: PubMed
    Score: 0.007
  47. RhoC maintains vascular homeostasis by regulating VEGF-induced signaling in endothelial cells. J Cell Sci. 2015 10 01; 128(19):3556-68.
    View in: PubMed
    Score: 0.007
  48. Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles. Oncotarget. 2014 Aug 15; 5(15):6453-65.
    View in: PubMed
    Score: 0.007
  49. Understanding protein-nanoparticle interaction: a new gateway to disease therapeutics. Bioconjug Chem. 2014 Jun 18; 25(6):1078-90.
    View in: PubMed
    Score: 0.007
  50. Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance. PLoS One. 2013; 8(11):e79167.
    View in: PubMed
    Score: 0.006
  51. Probing novel roles of the mitochondrial uniporter in ovarian cancer cells using nanoparticles. J Biol Chem. 2013 Jun 14; 288(24):17610-8.
    View in: PubMed
    Score: 0.006
  52. Inhibition of tumor growth and metastasis by a self-therapeutic nanoparticle. Proc Natl Acad Sci U S A. 2013 Apr 23; 110(17):6700-5.
    View in: PubMed
    Score: 0.006
  53. Inhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeutics. PLoS One. 2013; 8(3):e57522.
    View in: PubMed
    Score: 0.006
  54. Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo. Int J Cancer. 2013 Mar 01; 132(5):1201-12.
    View in: PubMed
    Score: 0.006
  55. Revealing the role of phospholipase Cß3 in the regulation of VEGF-induced vascular permeability. Blood. 2012 Sep 13; 120(11):2167-73.
    View in: PubMed
    Score: 0.006
  56. Identifying new therapeutic targets via modulation of protein corona formation by engineered nanoparticles. PLoS One. 2012; 7(3):e33650.
    View in: PubMed
    Score: 0.006
  57. Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future. Chem Soc Rev. 2012 Apr 07; 41(7):2943-70.
    View in: PubMed
    Score: 0.006
  58. Cancer nanotechnology: emerging role of gold nanoconjugates. Anticancer Agents Med Chem. 2011 Dec; 11(10):965-73.
    View in: PubMed
    Score: 0.006
  59. Switching the targeting pathways of a therapeutic antibody by nanodesign. Angew Chem Int Ed Engl. 2012 Feb 13; 51(7):1563-7.
    View in: PubMed
    Score: 0.006
  60. Efficient delivery of gold nanoparticles by dual receptor targeting. Adv Mater. 2011 Nov 16; 23(43):5034-8.
    View in: PubMed
    Score: 0.006
  61. A simple synthesis of a targeted drug delivery system with enhanced cytotoxicity. Chem Commun (Camb). 2011 Aug 14; 47(30):8530-2.
    View in: PubMed
    Score: 0.005
  62. Designing nanoconjugates to effectively target pancreatic cancer cells in vitro and in vivo. PLoS One. 2011; 6(6):e20347.
    View in: PubMed
    Score: 0.005
  63. Mechanism of anti-angiogenic property of gold nanoparticles: role of nanoparticle size and surface charge. Nanomedicine. 2011 Oct; 7(5):580-7.
    View in: PubMed
    Score: 0.005
  64. Inorganic nanoparticles in cancer therapy. Pharm Res. 2011 Feb; 28(2):237-59.
    View in: PubMed
    Score: 0.005
  65. Regulation of vascular endothelial growth factor receptor 2 trafficking and angiogenesis by Golgi localized t-SNARE syntaxin 6. Blood. 2011 Jan 27; 117(4):1425-35.
    View in: PubMed
    Score: 0.005
  66. Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis. Proc Natl Acad Sci U S A. 2010 Aug 17; 107(33):14541-6.
    View in: PubMed
    Score: 0.005
  67. Effect of nanoparticle surface charge at the plasma membrane and beyond. Nano Lett. 2010 Jul 14; 10(7):2543-8.
    View in: PubMed
    Score: 0.005
  68. Endothelial cell-specific chemotaxis receptor (ecscr) promotes angioblast migration during vasculogenesis and enhances VEGF receptor sensitivity. Blood. 2010 Jun 03; 115(22):4614-22.
    View in: PubMed
    Score: 0.005
  69. Sclerostin binds and regulates the activity of cysteine-rich protein 61. Biochem Biophys Res Commun. 2010 Jan 29; 392(1):36-40.
    View in: PubMed
    Score: 0.005
  70. Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adv Drug Deliv Rev. 2010 Mar 08; 62(3):346-61.
    View in: PubMed
    Score: 0.005
  71. Dopamine regulates phosphorylation of VEGF receptor 2 by engaging Src-homology-2-domain-containing protein tyrosine phosphatase 2. J Cell Sci. 2009 Sep 15; 122(Pt 18):3385-92.
    View in: PubMed
    Score: 0.005
  72. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res. 2008 Mar 15; 68(6):1970-8.
    View in: PubMed
    Score: 0.004
  73. Antiangiogenic properties of gold nanoparticles. Clin Cancer Res. 2005 May 01; 11(9):3530-4.
    View in: PubMed
    Score: 0.004
  74. Protein kinase C zeta transactivates hypoxia-inducible factor alpha by promoting its association with p300 in renal cancer. Cancer Res. 2004 Jan 15; 64(2):456-62.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.